Yahoo Web Search

  1. Yahoo Finance Results

  2. Better Buy: Celgene Corporation vs. Gilead Sciences

    Motley Fool via Yahoo FinanceOct 30 10:33 AM

    Shares of Celgene Corporation (NASDAQ: CELG) and Gilead Sciences Inc. (NASDAQ: GILD) have tumbled along with their industry despite strong growth for key drugs. Which of these ...

  3. Is Beaten-Down Celgene Corporation a Buy Now?

    Motley Fool via Yahoo FinanceOct 30 13:31 PM

    Celgene Corporation (NASDAQ: CELG) has been one of the worst-performing big biotech stocks of the past year even though the company has consistently reported impressive profit ...

    69.65-0.33 (-0.47%)

    at Fri, Nov 16, 2018, 16:00PM EST - U.S. Markets closed

    After Hours 69.65 N/A (N/A%)

    Nasdaq Real Time Price

    • Open 69.75
    • High 70.28
    • Low 68.93
    • Prev. Close 69.98
    • 52 Wk. High 110.81
    • 52 Wk. Low 68.91
    • P/E 19.37
    • Mkt. Cap 48.7B
  4. (GILD) : Free Stock Analysis Report Celgene Corporation (CELG) : Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Ultragenyx...

  5. CSX and Celgene CELG. Today, Zacks is promoting its ''Buy'' stock recommendations.

  6. 3 Hammered Healthcare Stocks to Buy Now

    Motley Fool via Yahoo FinanceNov 01 12:54 PM

    (NASDAQ: ALGN), Celgene Corporation (NASDAQ: CELG), and Ligand Pharmaceuticals Inc. (NASDAQ: LGND) have delivered less than thrilling news recently, but the market's reaction seems ...

  7. Celgene (CELG) closed the most recent trading day at $71.43, moving -1.41% from the previous trading session. Prior to today's trading, shares of the biotechnology company had lost 18.82% ...

  8. The Huge Amounts CEOs Are Spending on Midterms

    GoBankingRates via Yahoo FinanceNov 06 20:20 PM

    S&P 500 CEOs are contributing millions to the midterm elections. Amazon’s Jeff Bezos is the index’s top contributor, with over $10 million. The top five contributors have given money to both ...

  9. The wider-than-expected year-over-year loss was due to higher research & development (R&D), and general & administrative (G&A) expenses on lower revenues. Revenues of $11.5 million beat the Zacks Consensus Estimate of $8.3 million.

  10. 3 Top Biotech Stocks With P/Es Below 14

    Motley Fool via Yahoo FinanceNov 03 20:52 PM

    America's largest biotech has delivered monstrous gains in the past, but its aging lineup of blockbusters are losing ground and that has investors more than a little worried. This could be the ...

  11. Click to get this free report Celgene Corporation (CELG) : Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Vertex...